Lung cancer in solid organ transplant recipients-Reference-Cited by-同舟云学术

Lung cancer in solid organ transplant recipients

Published:2021-10-22 Issue:4 Volume:23 Page:19-25
ISSN:2412-6160
Container-title:Russian Journal of Transplantology and Artificial Organs
language:
Short-container-title:RJTAO

Author:

Nikulin A. V.¹,Pashkov I. V.¹,Yakunin Ya. S.¹

Affiliation:

1. Shumakov National Medical Research Center of Transplantology and Artificial Organs

Abstract

Lung cancer remains the leading cause of cancer mortality worldwide. Solid organ transplant recipients are at risk of developing malignant tumors, including lung cancer, due to long-term use of immunosuppressive drugs. Development of cancer, including lung cancer, in this patient cohort, has a number of peculiarities. Moreover, malignant tumors in these patients are difficult to treat and have a poorer prognosis. This review presents a study of the issues concerning the mechanisms of lung cancer development, screening methods and treatment in solid organ transplant recipients.

Publisher

V.I. Shimakov Federal Research Center of Transplantology and Artificial Organs

Subject

Transplantation,Immunology and Allergy

Reference52 articles.

1. Bade BC, Dela Cruz CS. Lung Cancer 2020: Epidemiology, Etiology and Prevention. Clin Chest Med Elsevier Inc. 2020; 41 (1): 1–24. doi: 10.1016/j.ccm.2019.10.001.

2. Wareham NE et al. Risk of de novo or secondary cancer after solid organ or allogeneic haematopoietic stem cell transplantation. J Cancer Res Clin Oncol Springer Berlin Heidelberg. 2019; 145 (12): 3125–3135. doi: 10.1007/s00432-019-03039-2.

3. Shtraichman O, Ahya VN. Malignancy after lung transplantation. Ann Transl Med. 2020; 8 (6): 416–416. doi: 10.21037/atm.2020.02.126.

4. Rousseau-Gazaniol C et al. Lung cancer in renal transplant recipients: A case-control study. Lung Cancer Elsevier Ireland Ltd. 2017; 111: 96–100. doi: 10.1016/j.lungcan.2017.07.011.

5. Acuna SA. Etiology of increased cancer incidence after solid organ transplantation. Transplant Rev Elsevier Inc. 2018; 32 (4): 218–224. doi: 10.1016/j.trre.2018.07.001.